Logo

Janssen and BMS Present Results of Milvexian in P-II AXIOMATIC-TKR Study for the Treatment of TKR Surgery at AHA 2021, Published in NEJM

Share this

Janssen and BMS Present Results of Milvexian in P-II AXIOMATIC-TKR Study for the Treatment of TKR Surgery at AHA 2021, Published in NEJM

Shots:

  • The P-II AXIOMATIC-TKR study evaluates the efficacy and safety of milvexian (qd/bid) vs enoxaparin (SC) in 1242 patients with elective TKR surgery
  • The trial met both of its pre-specified proof-of-principle requirements i.e., milvexian (bid) showed significant efficacy, reduction in the risk of postoperative VTE in a dose-dependent manner without increasing the risk of bleeding compared with enoxaparin & demonstrated a favorable antithrombotic profile across multiple doses
  • Milvexian is an FXIa inhibitor for the prevention and treatment of major thrombotic conditions. The results from the ongoing P-II AXIOMATIC-SSP study of milvexian for secondary stroke prevention are expected in H1’22

  Ref: Janssen | Image: Janssen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions